<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673880</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-A001-005</org_study_id>
    <nct_id>NCT01673880</nct_id>
  </id_info>
  <brief_title>Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Multi-cohort, Crossover Study of Relative Bioavailability of Tablet Versus Capsule Formulation of E2006 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized crossover study being conducted in three
      cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of
      three cohorts (approximately 12 subjects per cohort) and they will receive both a single dose
      of E2006 in capsule formulation and a single dose of E2006 in tablet formulation, in random
      sequence, at a 1:1 ratio. The doses to be tested will be 2.5 mg, 10 mg, and 25 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of E2006 of tablet vs. capsule formulations</measure>
    <time_frame>up to 336 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>36 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>E2006 2.5 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 10mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E2006 25 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006</intervention_name>
    <description>2.5 mg, 10 mg, and 25 mg E2006 tablets</description>
    <arm_group_label>E2006 2.5 mg</arm_group_label>
    <arm_group_label>E2006 10mg</arm_group_label>
    <arm_group_label>E2006 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Healthy males or females,

          -  ages 18 to 55 years

          -  Body mass index (BMI) &amp;gt;

          -  18 and 32 kg/m2 at Screening

        Exclusion:

          -  Female subjects who are nursing

          -  Subjects with a history of gastrointestinal surgery (hepatectomy, nephrectomy,
             digestive organ resection, etc.) that may affect PK profiles of E2006

          -  Subjects with a known history of clinically significant drug or food allergies

          -  Subjects with a known allergy or hypersensitivity to capsule or tablet ingredients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz Laurent</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

